Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA33
|
| gptkbp:brand |
gptkb:Entyvio
|
| gptkbp:CASNumber |
943609-66-3
|
| gptkbp:developer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:drugClass |
gptkb:immunosuppressant
|
| gptkbp:form |
solution for infusion
|
| gptkbp:halfLife |
25 days
|
| gptkbp:KEGGID |
D09913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
integrin α4β7 antagonist
|
| gptkbp:molecularWeight |
147 kDa
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:PubChem_CID |
DB09033
CHEMBL1743026 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea headache arthralgia upper respiratory tract infection |
| gptkbp:target |
integrin α4β7
|
| gptkbp:UNII |
6B4YK2V4U4
|
| gptkbp:usedFor |
gptkb:Crohn's_disease
ulcerative colitis |
| gptkbp:bfsParent |
gptkb:alpha-4_beta-7_integrin
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
vedolizumab
|